AveXis (NASDAQ:AVXS) has received an average recommendation of “Hold” from the twenty-two research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $125.45.
A number of brokerages recently issued reports on AVXS. Credit Suisse Group reiterated a “neutral” rating and issued a $139.00 price objective on shares of AveXis in a report on Wednesday, April 11th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $144.00 price objective (up previously from $110.00) on shares of AveXis in a report on Tuesday, February 20th. Mizuho set a $147.00 price objective on shares of AveXis and gave the company a “buy” rating in a report on Wednesday, March 14th. Zacks Investment Research lowered shares of AveXis from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. Finally, William Blair began coverage on shares of AveXis in a report on Monday, April 9th. They issued a “hold” rating for the company.
Shares of NASDAQ AVXS opened at $217.83 on Friday. The company has a market capitalization of $8.02 billion, a P/E ratio of -29.92 and a beta of 1.55. AveXis has a 1 year low of $217.72 and a 1 year high of $217.94.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.32) by ($2.88). equities analysts expect that AveXis will post -9.69 earnings per share for the current year.
In other news, VP James J. Litalien sold 5,000 shares of AveXis stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $119.44, for a total value of $597,200.00. Following the completion of the sale, the vice president now owns 8,800 shares in the company, valued at approximately $1,051,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $126.15, for a total transaction of $1,892,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,780 shares of company stock valued at $5,801,268. Company insiders own 18.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of AveXis by 57.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after acquiring an additional 453 shares in the last quarter. QS Investors LLC bought a new stake in shares of AveXis in the 4th quarter valued at $156,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of AveXis by 29.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,603 shares of the company’s stock valued at $198,000 after acquiring an additional 362 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after acquiring an additional 1,577 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new stake in shares of AveXis in the 4th quarter valued at $251,000. Institutional investors own 84.14% of the company’s stock.
AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.